MannKind Corp
NASDAQ:MNKD

Watchlist Manager
MannKind Corp Logo
MannKind Corp
NASDAQ:MNKD
Watchlist
Price: 6.84 USD -0.87% Market Closed
Market Cap: 1.9B USD
Have any thoughts about
MannKind Corp?
Write Note

Operating Margin
MannKind Corp

21.4%
Current
-42%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
21.4%
=
Operating Profit
57.3m
/
Revenue
267.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
MannKind Corp
NASDAQ:MNKD
1.9B USD
21%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
28%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
133.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-22%
Country US
Market Cap 1.9B USD
Operating Margin
21%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 312.7B USD
Operating Margin
28%
Country US
Market Cap 158.3B USD
Operating Margin
19%
Country US
Market Cap 115.9B USD
Operating Margin
40%
Country US
Market Cap 112.4B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 133.6B AUD
Operating Margin
26%
Country US
Market Cap 82.6B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.5B EUR
Operating Margin
-22%
No Stocks Found

MannKind Corp
Glance View

Market Cap
1.9B USD
Industry
Biotechnology

MannKind Corp. operates as a biopharmaceutical company. The company is headquartered in Danbury, Connecticut and currently employs 348 full-time employees. The company went IPO on 2004-07-28. The firm is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.

MNKD Intrinsic Value
5.81 USD
Overvaluation 15%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
21.4%
=
Operating Profit
57.3m
/
Revenue
267.2m
What is the Operating Margin of MannKind Corp?

Based on MannKind Corp's most recent financial statements, the company has Operating Margin of 21.4%.